vs

Side-by-side financial comparison of Organogenesis Holdings Inc. (ORGO) and Riley Exploration Permian, Inc. (REPX). Click either name above to swap in a different company.

Riley Exploration Permian, Inc. is the larger business by last-quarter revenue ($113.9M vs $37.2M, roughly 3.1× Organogenesis Holdings Inc.). On growth, Riley Exploration Permian, Inc. posted the faster year-over-year revenue change (11.2% vs -57.1%). Over the past eight quarters, Riley Exploration Permian, Inc.'s revenue compounded faster (3.9% CAGR vs -46.5%).

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

ORGO vs REPX — Head-to-Head

Bigger by revenue
REPX
REPX
3.1× larger
REPX
$113.9M
$37.2M
ORGO
Growing faster (revenue YoY)
REPX
REPX
+68.2% gap
REPX
11.2%
-57.1%
ORGO
Faster 2-yr revenue CAGR
REPX
REPX
Annualised
REPX
3.9%
-46.5%
ORGO

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
ORGO
ORGO
REPX
REPX
Revenue
$37.2M
$113.9M
Net Profit
$-70.4M
Gross Margin
30.8%
Operating Margin
-185.1%
38.3%
Net Margin
-61.8%
Revenue YoY
-57.1%
11.2%
Net Profit YoY
EPS (diluted)
$-3.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORGO
ORGO
REPX
REPX
Q1 26
$37.2M
$113.9M
Q4 25
$225.6M
$97.3M
Q3 25
$150.9M
$106.9M
Q2 25
$101.0M
$85.4M
Q1 25
$86.7M
$102.5M
Q4 24
$126.7M
$102.7M
Q3 24
$115.2M
$102.3M
Q2 24
$130.2M
$105.4M
Net Profit
ORGO
ORGO
REPX
REPX
Q1 26
$-70.4M
Q4 25
$43.7M
Q3 25
$21.6M
$16.3M
Q2 25
$-9.4M
$30.5M
Q1 25
$-18.8M
$28.6M
Q4 24
$7.7M
Q3 24
$12.3M
$25.7M
Q2 24
$-17.0M
$33.5M
Gross Margin
ORGO
ORGO
REPX
REPX
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
ORGO
ORGO
REPX
REPX
Q1 26
-185.1%
38.3%
Q4 25
28.1%
26.9%
Q3 25
13.7%
27.0%
Q2 25
-12.5%
33.7%
Q1 25
-30.9%
48.3%
Q4 24
8.1%
31.2%
Q3 24
5.4%
17.1%
Q2 24
-10.7%
50.9%
Net Margin
ORGO
ORGO
REPX
REPX
Q1 26
-61.8%
Q4 25
19.4%
Q3 25
14.3%
15.3%
Q2 25
-9.3%
35.7%
Q1 25
-21.7%
27.9%
Q4 24
6.1%
Q3 24
10.7%
25.1%
Q2 24
-13.1%
31.8%
EPS (diluted)
ORGO
ORGO
REPX
REPX
Q1 26
$-3.38
Q4 25
$0.31
$4.02
Q3 25
$0.11
$0.77
Q2 25
$-0.10
$1.44
Q1 25
$-0.17
$1.36
Q4 24
$0.05
$0.52
Q3 24
$0.09
$1.21
Q2 24
$-0.13
$1.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORGO
ORGO
REPX
REPX
Cash + ST InvestmentsLiquidity on hand
$91.4M
Total DebtLower is stronger
$240.7M
Stockholders' EquityBook value
$553.4M
Total Assets
$520.0M
$1.2B
Debt / EquityLower = less leverage
0.43×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORGO
ORGO
REPX
REPX
Q1 26
$91.4M
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Total Debt
ORGO
ORGO
REPX
REPX
Q1 26
$240.7M
Q4 25
$247.9M
Q3 25
$367.0M
Q2 25
$275.2M
Q1 25
$249.3M
Q4 24
$269.5M
Q3 24
$62.3M
$288.6M
Q2 24
$63.8M
$322.7M
Stockholders' Equity
ORGO
ORGO
REPX
REPX
Q1 26
$553.4M
Q4 25
$300.1M
$634.2M
Q3 25
$255.1M
$566.5M
Q2 25
$233.2M
$556.9M
Q1 25
$242.9M
$532.4M
Q4 24
$262.9M
$510.6M
Q3 24
$278.5M
$507.4M
Q2 24
$263.5M
$489.0M
Total Assets
ORGO
ORGO
REPX
REPX
Q1 26
$520.0M
$1.2B
Q4 25
$598.7M
$1.2B
Q3 25
$509.8M
$1.2B
Q2 25
$461.1M
$1.0B
Q1 25
$467.4M
$994.9M
Q4 24
$497.9M
$993.5M
Q3 24
$446.3M
$997.9M
Q2 24
$443.2M
$1.0B
Debt / Equity
ORGO
ORGO
REPX
REPX
Q1 26
0.43×
Q4 25
0.39×
Q3 25
0.65×
Q2 25
0.49×
Q1 25
0.47×
Q4 24
0.53×
Q3 24
0.22×
0.57×
Q2 24
0.24×
0.66×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORGO
ORGO
REPX
REPX
Operating Cash FlowLast quarter
$47.2M
Free Cash FlowOCF − Capex
$24.6M
FCF MarginFCF / Revenue
21.6%
Capex IntensityCapex / Revenue
41.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORGO
ORGO
REPX
REPX
Q1 26
$47.2M
Q4 25
$39.4M
$64.9M
Q3 25
$3.1M
$63.6M
Q2 25
$-32.9M
$33.6M
Q1 25
$-19.9M
$50.4M
Q4 24
$10.9M
$66.4M
Q3 24
$8.7M
$72.1M
Q2 24
$4.7M
$51.6M
Free Cash Flow
ORGO
ORGO
REPX
REPX
Q1 26
$24.6M
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
ORGO
ORGO
REPX
REPX
Q1 26
21.6%
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
ORGO
ORGO
REPX
REPX
Q1 26
41.3%
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
ORGO
ORGO
REPX
REPX
Q1 26
Q4 25
0.90×
Q3 25
0.14×
3.90×
Q2 25
1.10×
Q1 25
1.76×
Q4 24
1.43×
Q3 24
0.71×
2.81×
Q2 24
1.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons